Dimerix Limited (ASX:DXB)
0.5150
-0.0150 (-2.83%)
Oct 17, 2025, 4:10 PM AEST
Dimerix Revenue
In the fiscal year ending June 30, 2025, Dimerix had annual revenue of 5.59 million AUD with 1,271.12% growth. Dimerix had revenue of 5.3 million in the half year ending June 30, 2025, with 14,305.57% growth.
Revenue
5.59M
Revenue Growth
+1,271.12%
P/S Ratio
55.33
Revenue / Employee
n/a
Employees
n/a
Market Cap
309.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.59M | 5.18M | 1,271.12% |
Jun 30, 2024 | 407.47K | 370.68K | 1,007.64% |
Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
Jun 30, 2021 | 4.44M | 2.10M | 89.65% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Ramsay Health Care | 17.79B |
Sonic Healthcare | 9.65B |
Ansell | 3.06B |
Cochlear | 2.34B |
Regis Healthcare | 1.16B |
Telix Pharmaceuticals | 1.01B |
Neuren Pharmaceuticals | 218.86M |
Dimerix News
- 6 months ago - Biotech Dimerix lands $940m licensing deal for kidney drug sales - The Australian Financial Review